- Service Name
Poxel
- Industry
Biopharmaceutical, healthcare, metabolic diseases, chronic disease treatment
- Main Value Proposition
Poxel offers innovative, disease-modifying therapies for chronic metabolic diseases, aiming to improve patient outcomes through advanced scientific approaches.
- Description
Poxel is a clinical stage biopharmaceutical company focused on developing innovative treatments for chronic serious diseases with metabolic pathophysiology, particularly non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The company aims to provide safer and more effective therapies through its advanced pipeline of products.
- Key Features
Mid-stage products targeting NASH and rare metabolic diseases; First-in-class direct AMPK activator, PXL770; Commercialized product TWYMEEG® for type 2 diabetes in Japan; Strong leadership and experienced clinical teams
- Use Cases
Poxel's treatments are most valuable for patients suffering from NASH, rare metabolic diseases, and type 2 diabetes, particularly in clinical settings requiring advanced therapeutic options.
- Competitive advantages
Strong pipeline of mid-stage products with promising clinical results; Partnership with Sumitomo Pharma for the commercialization of Imeglimin in Japan; Expertise in targeting complex metabolic diseases
- Strengths
Poxel's strengths lie in its innovative pipeline, strong leadership, and a focused approach to addressing unmet medical needs in metabolic diseases.
- Positioning
Poxel positions itself as a leader in the biopharmaceutical industry, specializing in innovative treatments for chronic metabolic diseases, with a strong emphasis on scientific research and development.
- Audience
The target users include healthcare professionals, researchers in metabolic diseases, and patients with chronic metabolic conditions, particularly those affected by NASH and diabetes.
- CTA
View Our Candidates
- Tags
metabolic diseases
NASH
biopharmaceutical
innovative treatments
- Tagline
Experts in Developing Innovative Treatments for Metabolic Diseases
- Tone of Voice
Professional, informative, innovative
- Differentiation
Poxel differentiates itself by focusing on mitochondrial dysfunction and developing first-in-class products that target significant pathways in energy metabolism.
- Brand Positioning
Poxel's brand identity is centered around innovation, scientific excellence, and a commitment to improving patient health outcomes in the field of metabolic diseases.
- Founded
2009-01-01
- Founders
Pascale Fouqueray
Sophie Bozec
Sébastien Bolze
Thomas Kuhn